VAR2 PHARMACEUTICALS ApS: Financial statements 2022
CVR: 34621942
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
VAR2 PHARMACEUTICALS ApS (CVR 34621942) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -6,358,279 and a net result of DKK -6,805,156 compared with DKK -5,904,971 the year before. Equity in the 2022 report amounted to DKK 67,385,372. The solvency ratio was 96%. The company had 5 employees in the financial year.
- Gross Profit
- DKK -6,358,279
- Profit/Loss
- DKK -6,805,156
- Equity
- DKK 67,385,372
- Total Assets
- DKK 70,168,484
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -6.4 mio. | -6.8 mio. | 67.4 mio. | 5 |
| 2021 | - | -4.4 mio. | -5.9 mio. | 37 mio. | 7 |
| 2020 | - | -3.4 mio. | -5.4 mio. | 42.9 mio. | 8 |
| 2019 | - | -4.7 mio. | -6.9 mio. | 48.3 mio. | 8 |
| 2018 | - | -1.9 mio. | -4 mio. | 55.1 mio. | 6 |
Official annual report
Keep an eye on VAR2 PHARMACEUTICALS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
VAR2 PHARMACEUTICALS ApS has published its annual report for 2021. Gross profit came to DKK -4,433,183, and the net result was DKK -5,904,971.
As of April 1, 2022, Josef Rainer has joined the board of directors of VAR2 PHARMACEUTICALS ApS.
About VAR2 PHARMACEUTICALS ApS
VAR2 PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ali El-Salanti and Mads Daugaard. The board consists of Mads Daugaard (chair), Ali El-Salanti, Josef Rainer and Peter Schröcksnadel. The company is owned by ONCOMAL ApS and Københavns Universitet. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -21,739,014 and a net result of DKK -19,726,508 compared with DKK -21,006,013 the year before. Equity in the 2025 report amounted to DKK 82,032,248.